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We report the experience of 41 patients (21 males, 20 females;
mean age, 8.1 years; range, 0.2–22.6 years) treated with RIC and
allogeneic HSCT. Diagnoses consisted of malignancies in 24 (20
hematologic and 4 refractory neuroblastoma) and nonmalignant
disorders in 17: immunodeﬁciencies in 6, metabolic disorders in 5,
hemoglobinopathies in 4, and aplastic anemia in 2. Twelve patients
had prior HSCT (7 autologous and 5 allogeneic). Recipient’s racial
origins included 22 Caucasian, 10 Hispanic, 7 African American,
and 2 Asian. A standardized RIC regimen comprised of ﬂudara-
bine, 30 mg/m2 for 6 days (days 10 to 5), followed by intrave-
nous busulfan, 0.8–1 mg/kg for 8 doses or targeted busulfan at
AUC 4000 mmol/min for 2 doses (days 5 and 4) and equine
ATG, 40 mg/kg or rabbit ATG, 2 mg/kg for 4 days (days 4
through1) was administered. Graft-versus-host disease (GVHD)
prophylaxis was cyclosporin A (CsA) alone in 19 patients and CsA
and mycophenolate mofetil in 22 patients. Growth factor support
was not used. Stem cell sources included 27 unrelated donors and
14 related donors; 34 of 41 sources were peripheral blood stem
cells. We also assessed engraftment by determining the number of
days required to achieve  50% and  95% donor chimerism
(Do-chim) by VNTR in total leukocyte and T-lymphocyte (CD3)
populations.
The median cell doses infused were 5.8  108 MNC/kg and 2 
106 CD34 cells/kg. Seven of 41 patients failed to engraft, and 3
patients were not evaluable due to early deaths from toxicity (in 2)
or relapse (in 1). Four of 16 evaluable patients with nonmalignant
disorders failed to engraft versus 3 of 22 with malignancies. Pa-
tients failing to engraft were younger (median age, 6.3 vs 8.8 years)
and weighed less (median weight, 18 vs 27 kg), but received lower
cell infusion doses (3.9 vs 5.9  108 MNC/kg; P  .05). The
median time to a postnadir ANC of 500/L was 16.5 days, and
unsupported platelet count  20,000/L was 19 days. Data shown
in the table indicate trends for more rapid achievement of Do-chim
in patients treated for malignancy. Also, within the 14 malignancy
patients, those with clinically signiﬁcant acute (II-IV) and/or ex-
tensive chronic GVHD demonstrated faster Do-chim.
These measures of engraftment may provide a reproducible com-
parison of engraftment in the setting of RIC and resulting mixed
chimeric states. These parameters may provide insight to promote
engraftment or to balance a desired graft-versus-tumor effect in
patients with malignancies versus limitation of GVHD for patients
with no beneﬁt from an excessive alloimmune response.
Table 1. Median Number of Days to Achieve Donor-Chimerism
Leukocyte
Do-chim
50
Leukocyte
Do-chim
95
Lymphocyte
Do-chim
50
Lymphocyte
Do-chim
95
Evaluable Pts
(n  26) 18 26 25 33
Non-malignant
Disorders
(n  11) 19 53 26 82.5
Malignancy Pts
(n  15) 13 25 21 27
Malignancy &
GVHD
(n  7) 13 17 20 19
Malignancy
without
GVHD
(n  8) 16 32.5 26.5 39
245
CHANGE OF RISK FACTORS FOR TREATMENT-RELATED MORTALITY IN
CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR MALIGNANT AND NONMALIGNANT DISEASES
Peters, C.1, Lawitschka, A.1, Atarbaschi, A.1, Lion, T.2, Poetschger, U.2,
Fritsch, G.2, Fischer, G.3, Rosenmayr, A.3, Gadner, H.1,
Matthes-Martin, S.1 1St. Anna Children’s Hospital; 2Children Cancer
Research Institute; 3University Clinic for Blood Group Serology and
Transfusion Medicine; 4Austrian Stem Cell Registry, Vienna, Austria.
Allogeneic hematopoietic stem cell transplantation (HSCT) of-
fers a high chance for cure in patients with nonmalignant disorders.
However, acute and late complications as consequence of the
conditioning regimen and severe immunosuppression are still a
matter of concern. Only few studies speciﬁcally focused on the risk
for treatment-related mortality (TRM) in children. To evaluate
factors inﬂuencing the outcome after HSCT we retrospectively
analyzed 342 children given allogeneic SCT. The median age was
8.7 years; 230 patients suffered from hematologic malignancies,
112 from nonmalignant disorders (SAA, immunodeﬁciency syn-
dromes, metabolic disorders, thalassemia, sickle cell disease, he-
mophagocytic syndromes). The 360-day TRM (in nonmalignant
diseases, 0.17) was inﬂuenced by donor type (HLA-identical sibling
donors vs phenotypically matched family or unrelated donors vs
mismatched donors), time of SCT (before and after 1997), stage of
disease (early vs advanced), conditioning regimen (myeloablative vs
reduced), graft manipulation (T-cell depletion vs no TCD) and
history of severe organ dysfunction and/or infections. Most fre-
quent causes of death were organ toxicity, acute GvHD, and
infections. The following factors were independent risk factors for
TRM: graft failure, resistant disease, CMV IgG-negative donors
for CMV IgG-positive patients, HLA mismatch  2 alleles, TCD
graft, and history of severe toxicity and/or infection. The pattern of
severe adverse events changed over time. In the ﬁrst years, GvHD
was the most frequent life-threatening complication, followed by
toxicity and infections. More recently, viral infections are the
major reason for TRM, particularly in patients transplanted from
HLA-mismatched donors given T-cell–depleted grafts. The cu-
mulative incidence of TRM in patients transplanted after 1997 was
0.06 from matched sibling donors, 0.14 from unrelated donors, and
0.27 and from HLA-mismatched donors. Factors associated with
improved survival incuded the quality of HLA typing (high-reso-
lution techniques in HLA class I and II), reduced intensity condi-
tioning, monitoring and preemptive treatment (pharmacologic and
virus-speciﬁc cell support) of viral infections, and experience (cen-
ter size  10 allogeneic SCTs vs  10 per year). We conclude that
today, the risk for TRM especially in children with nonmalignant
diseases undergoing HSCT could be reduced by multidisciplinary
approaches focusing the enhancement of immunologic reconstitution.
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TREATMENT OF PEDIATRIC PATIENTS WITH SANFILIPPO SYNDROME
(MPS IIIA AND IIIB) WITH UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION
Kurtzberg, J.1, Szabolcs, P.1, Wood, S.1, Ciocci, G.1, Driscoll, T.1,
Prasad, V.1, Parikh, S.1, Martin, P.L.1, Allison, J.1, Escolar, M.L.2
1Duke University Medical Center, Durham, NC; 2University of North
Carolina at Chapel Hill, Chapel Hill, NC.
Umbilical cord blood transplantation (UCBT) favorably alters
the natural history of young pediatric patients with Hurler syn-
drome (MPS I). We asked whether it would also be effective for
patients with Sanﬁlippo syndrome (MPS III). Patients with San-
ﬁlippo syndrome have less somatic and more CNS disease than
patients with other MPS syndromes. They are typically diagnosed
between 3 and 5 years of age. Without treatment, they develop
severe neurologic dysfunction, deafness, inability to speak or am-
bulate, and severely autistic behaviors. Death occurs between 10
and 13 years of age. Currently, allogeneic stem cell transplantation
(SCT) is the only way to deliver healthy enzyme to the brain. We
hypothesized that children with Sanﬁlippo syndrome would beneﬁt
from UCBT, particularly if it was performed early in the course of
the disease. Between February 2001 and April 2004, 12 children
(age 10–59 months, 75% male, 100% Caucasian) underwent
UCBT. All were prepared for transplantation with myeloablative
chemotherapy (busulfan/cyclophosphamide/ATG), and all re-
ceived prophylaxis against GvHD with cyclosporine and steroids.
They were transplanted with unrelated donor UCB grafts match-
ing at 6/6 (n  1), 5/6 (n  7), and 4/6 (n  4) HLA loci,
containing a median of 6.5 107 nucleated cells/kg and 1.42 105
CD34 cells/kg. Donor cell engraftment (ANC 500/L) occurred
in 9 of 12 children in a median of 24 days. Platelet engraftment
(platelet count 50K/L untransfused) occurred in 7 of 12 children
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in a median of 144 days. Grade II acute GvHD occurred in 3 of 8
engrafting patients. No patient developed extensive chronic
GvHD. Five patients did not survive; causes of death were graft
failure with viral infection in 3 children and viral infection in 2.
Seven children 58% are surviving for 6–43 months (median, 24
months) posttransplantation. All surviving children have shown
stabilization of disease progression. Children transplanted before
age 3 years have continued to gain developmental skills including
speech, albeit at a slower-than-normal pace. All children exhibit
some degree of autistic behavior but remain relatively calm and
happy without major sleep disturbances or aggressive behaviors.
Four of the surviving children are now over 4.5 years old, and all
appear to have higher neurocognitive functioning than untreated
Sanﬁlippo patients of similar age. We conclude that UCBT im-
proves the quality of life for patients with Sanﬁlippo syndrome.
Transplantation before age 2 years allows for continued cognitive
and developmental gains.
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REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMEN FOR
CHILDREN WITH MARROW STEM CELL DEFECTS (MSCD) OR LEUKEMIA
Horn, B.1, Baxter-Lowe, L.A.1, McMillan, A.1, Quinn, M.1,
DeSantes, K.2, Cowan, M.1 1University of California San Francisco,
San Francisco, CA; 2University of Wisconsin, Madison, WI.
Two major problems with busulfan/cyclophosphamide-contain-
ing conditioning regimens for children are acute toxicities (mu-
cositis and VOD) and graft failure/rejection. We have prospec-
tively evaluated a conditioning regimen using targeted dosing of IV
busulfan, ﬂudarabine, and rabbit ATG for its toxicity and efﬁcacy.
Patients included 19 children receiving HLA-matched related or
unrelated transplantation for MSCD, including thalassemia, aplas-
tic anemia (AA), metabolic diseases, congenital neutropenia, and
primary immunodeﬁciencies (n 15), and leukemia/MDS (n 3).
The targeted average steady-state concentration (Css) of busulfan
was 600 ng/mL for the cases of MSCD and 900 ng/mL for the
cases of leukemia/MDS. Donors were well HLA-matched unre-
lated volunteers (n  11), unrelated cord blood (n  1), and
HLA-matched relatives (n  6). The most common toxicity was
mucositis, which developed in 1/3 of the patients. None of the
patients developed VOD. All patients showed marrow engraftment
by 28 days. However, 2 of 19 patients, 1 with AA and the other with
adrenoleukodystrophy, rejected the graft by 6 weeks posttransplan-
tation. Two additional patients, 1 with mannosidosis and 1 with
thalassemia, had graft failure 6 months posttransplantation. Three
of these 4 were recipients of matched unrelated donor marrow
grafts, and 1 received related bone marrow graft. Three of the 4
patients were successfully retransplanted using a TBI-containing
regimen. There were 2 deaths, 1 from a preexisting CMV infection
in a child with Wiskott-Aldrich syndrome and 1 from complica-
tions related to graft rejection. The long-term disease-free survival
was 89%  7%, with a median follow-up of 27 months (range,
4–41 months), including the patients that needed second trans-
plants. The durable engraftment rate was 80%. We established a
quantitative PCR assay using short-tandem repeats (STRs) to
monitor engraftment in blood and bone marrow in cell subsets
including CD3, CD19, CD14/15, and CD34. Full (n  6) or
partial (n  9) donor chimerism was achieved in 15 evaluable
patients. Neither the results of early engraftment studies ( 30
days) nor the percentasge of donor CD3 cells were predictive of
ultimate engraftment outcome. Five of 9 patients with durable
mixed chimerism had  50% donor CD3 cells from 123–420
days posttransplantation. These results indicate that substituting
ﬂudarabine for cyclophosphamide can reduce toxicity with respect
to both mucositis and VOD, but that alternative regimens need to
be developed to improve durable engraftment.
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LOW TRANSPLANT-RELATED MORTALITY AFTER STEM CELL TRANS-
PLANTATION WITH IV BUSULFAN-BASED CONDITIONING IN PEDIAT-
RIC PATIENTS
Bolotin, E., Cooper, L., Synold, T., Sweetman, R., Mao, J., Palmer, J.,
Rosenthal, J. City of Hope, Duarte, CA.
High-dose busulfan is widely used in allogeneic and autologous
marrow transplantation preparative regimens.We evaluated the safety
and toxicity of IV busulfan (Bu) in combination with variety of che-
motherapeutic agents, including cytoxan, cytoxanVP16, melphalan,
and TBIBuVP16, as preparative therapy for stem cell transplan-
tation in pediatric patients. The length of follow up study was 3–40.3
months. Twenty-ﬁve pediatric patients (a total of 30 transplantation
procedures) with hematologic malignancies (n  11), solid tumors
(n  6), and nonmalignant disorders (n  8) were evaluated. Six
patients underwent autologous transplantation (5 with tandem trans-
plantation), and 19 patients underwent HLA-matched sibling alloge-
neic transplantation. The sources of the stem cells were peripheral
stem cells in 21, bone marrow in 7, and cord blood in 2.
All but 2 patients engrafted. ANC 500 was achieved at day 10–25
(median, day 13), and platelets  20 109 were achieved at day
14–85 (median, day 24). Grade 3–4 liver toxicities were diagnosed
in 17.3% of all patients; grade 3–4 pulmonary toxicities, in 10.9%.
There was no mortality in the ﬁrst 100 days after transplantation.
Pharmakokinetic studies showed a wide variability of busulfan
levels. The mean AUCs achieved after administration of the initial
test dose was 848.0 (461.1–1300.4). Adjustment of the IV busulfan
dose was made in 7 patients (28%). All doses were increased.
Individualization of busulfan doses has been recommended to ob-
tain sufﬁcient dose intensity to achieve engraftment while avoiding
relapse and toxicity. Published data demonstrated that using the IV
formulation of busulfan reduces variability in busulfan levels in both
adult and pediatric patients. However, most of the studies evaluated
IV busulfan in combination with cytoxan. We found that IV busulfan
in pediatric patients is generally well tolerated in combination with
cytoxan, melphalan, TBI, VP-16, and ﬂudarabine.
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TARGETED RADIOTHERAPY TO THE SKELETON USING 166HO-DOTMP
WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PATIENTS
WITH BONE-ONLY METASTATIC BREAST CANCER
Champlin, R.E., Booser, D., Rondon, G., Williams, P.A., Wendt, R.,
Hortobagyi, G., Ueno, N., Podoloff, D. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
The skeleton is the most frequent site of metastatic disease in breast
cancer. A subset of patients develop bone-dominant disease without
metastases to other organs. An attractive strategy is to utilize bone-
targeted radiotherapy. This study was designed to determine the
safety and preliminary efﬁcacy of 166Ho-DOTMP, which localizes to
bone, providing radiation to adjacent marrow and malignant cells.
The limiting toxicity is myelosuppression, which can be overcome by
autologous stem cell transplantation. We studied this strategy in
patients with breast cancer metastatic to conﬁned to the bone.
Treatment occurred between 1997 and 1999. Patients were eli-
gible if they were  65 years of age, had bone-only disease, had an
estrogen receptor–negative tumor, or had failed hormonal therapy.
A 30-mCi tracer dose was administered to assess targeting and to
calculate the therapeutic dose. The therapeutic dose was adminis-
tered in one of 2 dose levels, either 22 Gy (n  3) or 28 Gy (n 
3). Treatment was followed by autologous stem cell transplantation
when the ongoing radiation dose to marrow was  1 cGy/hour.
The 6 subjects received a median of 1548 mCi (range, 870–2065
mCi) of 166Ho DOTMP. There was selective uptake in the bone,
particularly in osteoblastic metastases; unbound drug was excreted
in the urine. The most common toxicities were mild nausea and
vomiting. None of the patients experienced grade  3 acute tox-
icity except for the expected profound myelosuppression. All pa-
tients had prompt hematologic recovery. Two patients developed
hemorrhagic cystitis at approximately 2 years following therapy,
which resolved in both cases. One of these patients also had GI
bleeding and pseudomembranous colitis unrelated to the 166Ho
DOTMP treatment. One patient developed MDS, but was found
to have a preexisting trisomy-8 by FISH analysis from the periph-
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